Sartorius Stedim Biotech (CHIX:DIMP) Ending Cash Position: €204 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:DIMP Sartorius Stedim Biotech SA CHIX:DIMP
82 GF Score
Price €187.40
GF Value €201.06
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Sartorius Stedim Biotech Ending Cash Position?

Sartorius Stedim Biotech CHIX:DIMP 82 Ending Cash Position is €204 Mil as of Jun. 2026. GuruFocus rates CHIX:DIMP with a GF Score™ of 82/100 and a GF Value™ of €201.06 (Fairly Valued). The stock has 5 warning signs investors should review.

Sartorius Stedim Biotech's Ending Cash Position for the quarter that ended in Jun. 2026 was €204 Mil.

Sartorius Stedim Biotech's quarterly Ending Cash Position increased from Dec. 2025 (€426 Mil) to Mar. 2026 (€521 Mil) but then declined from Mar. 2026 (€521 Mil) to Jun. 2026 (€204 Mil).

Sartorius Stedim Biotech's annual Ending Cash Position increased from Dec. 2023 (€117 Mil) to Dec. 2024 (€679 Mil) but then declined from Dec. 2024 (€679 Mil) to Dec. 2025 (€426 Mil).

Sartorius Stedim Biotech Ending Cash Position Related Terms

Sartorius Stedim Biotech Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Sartorius Stedim Biotech's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sartorius Stedim Biotech Ending Cash Position Chart

Sartorius Stedim Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 223.60 107.10 116.60 678.90 426.10

Sartorius Stedim Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 699.30 298.70 426.10 521.20 203.90
CHIX:DIMP
82GF Score
Sartorius Stedim Biotech SA CHIX:DIMP
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sartorius Stedim Biotech Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Sartorius Stedim Biotech's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=678.9+-252.8
=426

Sartorius Stedim Biotech's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=521.3+-317.4
=204

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €204 Mil mean?
Sartorius Stedim Biotech (CHIX:DIMP) has a Ending Cash Position of €204 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sartorius Stedim Biotech and its competitors.
Is Sartorius Stedim Biotech's Ending Cash Position too high?
Sartorius Stedim Biotech's current Ending Cash Position is €204 Mil. Overall, Sartorius Stedim Biotech has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Ending Cash Position compare to ISRG and BDX?
Sartorius Stedim Biotech's Ending Cash Position of €204 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sartorius Stedim Biotech and its competitors. Sartorius Stedim Biotech's current Ending Cash Position is €204 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Fairly Valued. The stock's GF Value™ is €201.06, compared to a current price of €187.40 — trading 6.8% below its estimated fair value. The current Ending Cash Position is €204 Mil. Sartorius Stedim Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current Ending Cash Position is €204 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued. The current stock price of €187.40 is trading 6.8% below its estimated GF Value™ of €201.06. GuruFocus considers Sartorius Stedim Biotech to be Fairly Valued.

Key valuation signals for CHIX:DIMP:

  • Ending Cash Position: €204 Mil
  • GF Value™: €201.06 vs. price of €187.40 (6.8% below fair value)
  • GF Score™: 82/100 with 5 warning signs

No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sartorius Stedim Biotech Business Description

Address Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
82GF Score

Get the complete analysis for CHIX:DIMP

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€187.40
Price
€201.06
GF Value